BioAtla (BCAB) Non-Current Deffered Revenue (2020 - 2021)
BioAtla's (BCAB) quarterly Non-Current Deffered Revenue came in at $1.7 million in Q3 2021, down 7.61% quarter-over-quarter from $1.8 million in Q2 2021.
BioAtla (BCAB) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
BioAtla's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $1.7 million for Q3 2021.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $1.7 million in Q3 2021; TTM through Sep 2021 was $1.7 million, a N/A change from a year earlier, with the FY2020 full-year figure at $2.0 million, changed N/A from the prior year.
- Non-Current Deffered Revenue fell to $1.7 million in Q3 2021 per BCAB's latest filing, from $1.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $2.0 million in Q4 2020 and bottomed at $1.7 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BioAtla | 5.74 Mn | 5.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 1.70 Mn |
| Jun 30, 2021 | 1.84 Mn |
| Mar 31, 2021 | 1.95 Mn |
| Dec 31, 2020 | 2.02 Mn |